Patents Examined by David M Shim
  • Patent number: 12110299
    Abstract: The present invention provides a novel thiazole derivative or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The thiazole derivative or pharmaceutically acceptable salt thereof according to the present invention has selective inhibitory activity against cyclin-dependent kinase (CDK) and thus can be used as a preventive or therapeutic agent for various diseases associated with CDK.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 8, 2024
    Assignee: YUNGJIN PHARM. CO., LTD.
    Inventors: Kwang Ok Lee, Jakyung Yoo, Jun Hee Lee, Mijung Lee, Kangwoo Lee, Jieun Min
  • Patent number: 12083099
    Abstract: The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-COV-19 and the viral protease inhibitor is E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; (R)-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl)thiazolidine-4-carboxamide; R)—N-allyl-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethylthiazolidine-4-carboxamide; (4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid or salts thereof.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: September 10, 2024
    Assignee: Accencio LLC
    Inventors: Kevin Brown, Kevin Brogle
  • Patent number: 12071423
    Abstract: The embodiments of present invention provide processes for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: August 27, 2024
    Assignee: Eli Lilly and Company
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Patent number: 12065437
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: August 20, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Patent number: 12016864
    Abstract: This invention relates to LOX enzyme-inhibiting compounds in accordance with Formula I or Formula II, or a pharmaceutically acceptable salt or hydrate thereof: and pharmaceutical compositions comprising the compounds. Such compounds and compositions can be useful in treating a variety of conditions, diseases, and disorders including, but not limited to, fibrotic disorders, proliferative disorders, cardiovascular disorders, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, and neurological and neuropsychiatric conditions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: June 25, 2024
    Assignee: Anovia Biosciences, Inc.
    Inventors: Michael Clare, Juan Du, Xiang Li, Ronggang Liu
  • Patent number: 12006314
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: June 11, 2024
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
  • Patent number: 12006305
    Abstract: Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obicetrapib, and salts thereof are also provided, including obicetrapib HCl and a mesylate salt for the use in the synthesis of obicetrapib and amorphous obicetrapib hemicalcium.
    Type: Grant
    Filed: July 3, 2023
    Date of Patent: June 11, 2024
    Assignee: NewAmsterdam Pharma B.V.
    Inventors: Sheng Cui, Andreas René Rötheli, Christopher J. Borths, Muneki Kishida
  • Patent number: 11999715
    Abstract: Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: June 4, 2024
    Assignee: BIOGEN MA INC.
    Inventors: Felix Gonzalez Lopez de Turiso, Zhili Xin, Martin Himmelbauer, John H. Jones
  • Patent number: 11980618
    Abstract: The invention relates to nitric oxide releasing phosphodiesterase type 5 (PDE5) inhibitors of formula or a stereoisomer or a pharmaceutically acceptable salt thereof: useful for the treatment of ocular condition associated with elevated intraocular pressure such as ocular hypertension, glaucoma or retinopathies.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 14, 2024
    Assignee: NICOX S.A.
    Inventors: Nicoletta Almirante, Stefania Brambilla, Laura Storoni, Francesco Impagnatiello, Elena Bastia
  • Patent number: 11975008
    Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I characterized by an XRPD pattern substantially the same as shown in FIG. 1 and uses thereof are described herein.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: May 7, 2024
    Assignee: GALAPAGOS NV
    Inventors: David Alonzo, Bei Li, Dimitrios Stefanidis
  • Patent number: 11964982
    Abstract: Compounds for treating cancer and, particularly, to compounds that are 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione analogues and their use as anticancer agents.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: April 23, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Vinuta Kamat, Rangappa Santosh, Boja Poojary, Manohar S. Kugaji, Vijay M. Kumbar, Mohamed A. Morsy, Bandar Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha
  • Patent number: 11931343
    Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: March 19, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Beatty, Laurent Pierre Paul Debien, Samuel Lawrie Drew, Jeremy Fournier, Rebecca Louise Grange, Steven Donald Jacob, Jenna Leigh Jeffrey, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal, Jay Patrick Powers, Anh Thu Tran, Rhiannon Thomas-Tran, Xuelei Yan
  • Patent number: 11925641
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: March 12, 2024
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventors: Yinon Ben-Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph P. Vacca, Dansu Li
  • Patent number: 11925640
    Abstract: Provided herein are methods and materials for improving arteriovenous fistula (AVF) maturation and/or maintaining AVF functionality. For example, methods and materials for using one or more senolytic agents to improve AVF maturation, to maintain AVF functionality, and/or to maintain the patency of an AVF are provided. Methods and materials for using one or more senolytic agents to maintain functionality and/or patency of a venous graft (e.g., a venous graft that bypasses an occluded artery) also are provided.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: March 12, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Karl A. Nath, James L. Kirkland, Tamar Tchkonia
  • Patent number: 11918568
    Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 5, 2024
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Tsuyoshi Nakamura, Mayuko Akiu, Takashi Tsuji, Jun Tanaka, Koji Terayama, Mika Yokoyama, Anthony B. Pinkerton, Edward Hampton Sessions
  • Patent number: 11866436
    Abstract: Provided are a compound of the formula: (5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: January 9, 2024
    Assignee: Cambridge Enterprise Limited
    Inventors: Marko Juhana Hyvonen, Paul Brear, David Robert Spring, Paul Glossop
  • Patent number: 11851436
    Abstract: The present disclosure relates to a compound of Formula (0): a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof. The present disclosure also relates to uses of the compound.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: December 26, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Philip Reigan, Kimberly A. Casalvieri
  • Patent number: 11827618
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: November 28, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Patent number: 11814382
    Abstract: Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: November 14, 2023
    Assignee: FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD.
    Inventors: Shengbin Zhang, Ning Li, Tao Yu, Yusheng Fu, Jiahu Wu, Chengde Wu
  • Patent number: 11814363
    Abstract: This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 14, 2023
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Akihiro Hashimoto, Wei Ma, Lee M. Katrincic